BTK and B-cell non-Hodgkin lymphoma: The introduction of BTK inhibitors has revolutionized the treatment landscape of B-cell lymphomas by disrupting the pathological mechanisms in malignant B cells, leading to improved drug response and reduced toxicity (Wang et al., 2021).